NCT06164561Recruiting
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
18F-FAPI PET/MRI Imaging in the Diagnosis and Monitoring of Therapeutic Effect of Myelofibrosis: a Prospective Observational Study.
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 57 (estimated)
- First submitted
- 23 Nov 2023
- Start date
- 21 Nov 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06164561
What you commit to
- Study type: Observational
- Planned participants: 57
- From 21 Nov 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current infection was present within 1 week before PET examination.
- Have received glucocorticoid therapy within 2 weeks before PET imaging examination.
- Using granulocyte colony-stimulating factor (G-CSF) within 4 weeks prior to PET imaging.
Other illness
- Other malignancies, autoimmune diseases, or chronic active infections were diagnosed within 1 year before the diagnosis of myelofibrosis.
Other
- Inability or unwillingness to provide informed consent.
- Pregnant or lactation.
- Unable to follow protocol to complete follow-up.
Who the study is looking for
- Patients with primary myelofibrosis or myelofibrosis secondary to myeloid tumors were diagnosed according to the diagnostic criteria of who 2022.
- Stable vital signs, ECOG score ≥ 2 points, tolerate and cooperate to complete 18F-FDG PET/CT and 18F-FAPI PET/MRI examination.
- The interval between imaging ,hematologic, cytogenetic and pathology was \< 2 weeks.
- Willing to accept 18F-FDG PET/CT and 18F-FAPI PET/MRI , sign the informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.